Kornimate/medical-research-clean huggingface dataset:
rheumatoid arthritis treatment and biopsy study assessing certolizumab pegol (cimzia)

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to conduct an investigator-sponsored study to determine the potential immunomodulatory effects of certolizumab pegol (czp) treatment at the site of disease activity (synovial lining) in subjects with rheumatoid arthritis (ra), using pre treatment and post treatment arthroscopic synovial biopsies and ex vivo on gene expression.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent document * subjects must be at least 18 years of age or older * subject must be willing and able to comply with scheduled visits, arthroscopy, laboratory tests, and other procedures * diagnosis of ra based on american college of rheumatology (acr) 1987 revised criteria * active disease at screening visit * methotrexate taken continuously for at least 12 weeks at a stable dosage * sexually active women of child-bearing potential and men whose partners are women of child-bearing potential are required to use adequate contraceptive methods during participation on this trial * treatment with non-steroidal anti-inflammatory drugs (nsaids)and oral corticosteroids (less than or equal to 10 mg/day prednisone or equivalent)is accepted exclusion criteria: * diagnosis of any other inflammatory arthritis * history of infected joint prosthesis that is still in situ * history of allergy to local anesthetic agents * pregnant or lactating women * current or recent history of uncontrolled clinically significant conditions(e.g..,kidney disease, liver disease, class iii or iv congestive heart failure, according to the new york heart association) * history or suspected demyelinating disease of the central nervous system, e.g. multiple sclerosis or optic neuritis * current participation in clinical trial

Keywords: rheumatoid arthritis cimzia certolizumab pegol arthroscopic synovial biopsy office based procedure biologic tumor necrosis factor (tnf) anti-tnf
influence of virtual reality on myocardial revascularization

Conditions: Myocardial Infarction

Summary: coronary artery disease is a dysfunction characterized by the narrowing of the coronary arteries in due to the accumulation of atheromatous plaques. the surgery of myocardial revascularization is a surgical procedure of choice performed in individuals with to improve symptoms and survival. cardiovascular surgeries of this size in an extended time of rest after the procedure. such immobility may have repercussions to the functionality of the individual. thus, the early mobilization with the use of reality in the intensive care units (icu) emerges as a potential means of of complications in the postoperative period of cardiac surgery.

the study will be performed at the icu coronary artery of the hospital de clínicas gaspar viana de belém-pará. 40 volunteers will participate in the study. preoperative period of myocardial revascularization. the oxidative stress (by the method called optical morphology by oxidative stress, using capillary blood drops), the modulation autonomic heart rate (with a polar® model rs800cx) and motor function (through the medical research council scale), before and after the application of protocol for cardiac rehabilitation with ergometer, virtual reality and ambulation. volunteers will be randomized into a control group who receive the cardiac rehabilitation protocol from the hospital and the early mobilization group, which will receive the cardiac rehabilitation protocol plus virtual reality training using wii video game from nintendo.

Eligibility criteria:
inclusion criteria: * male patients over 50 years of age to 80 years * body mass index (bmi) between 20 and 30 bmi kg / m2 * candidates for elective and conventional myocardial revascularization surgery * hemodynamic stability with or without the use of positive inotropes exclusion criteria: * patients with previous pulmonary diseases, with ejection fraction below 35% or greater than 54% * undergo concomitant surgeries and who underwent surgical reoperation and intraoperative death * also excluded are those with motor and neurological deficits, as well as contraindications for performing 6mwt * orthopedic limitations * unstable angina, hr\> 120 bpm at rest, systolic pressure\> 180 mmhg or diastolic\> 100 mmhg.

Keywords: virtual reality physical therapy myocardial revascualrization
b-cd30 + hodgkin lymphoma international multi-center retrospective study of treatment practices and outcomes

Conditions: Classical Hodgkin Lymphoma; Relapsed or Refractory Classical Hodgkin Lymphoma

Summary: the purpose of this study is to describe progression-free survival (pfs) in participants with relapsed or refractory classical hodgkin lymphoma (rrhl), defined as the time from initiation of first treatment for rrhl to first documentation of relapse or disease progression, or death.

this is a retrospective, non-interventional study of participants with newly-diagnosed chl, or with rrhl. the study will review the medical records of participants to describe participant's demographics, disease characteristics, treatments received, outcomes, health resources used by the participants, and adverse events that are associated with treatments, and resources used for treatment. the study will enroll approximately 50 to 100 participants in each group at each of the 13 participating countries. based on the diagnosis of the disease, participants will be assigned to one of the following groups: group 1: chl group 2: rrhl this multi-center trial will be conducted in argentina, australia, china, colombia, hong kong, mexico, republic of korea, russia, saudi arabia, singapore, south africa, taiwan, and turkey. the data for group 1 and group 2 will be collected from date of chl or rrhl diagnosis until the date of death (or the date when the participant was last known to be alive, whichever occurs first).

Eligibility criteria:
inclusion criteria: 1. participants newly diagnosed with high-risk stage iib-iv chl (for group 1) or rrhl (for group 2) between 01 january 2010 and 31 december 2013. 2. age greater than or equal to (\>=) 18 years at diagnosis of chl (group 1) or rrhl (group 2). 3. alive or deceased. 4. written informed consent is obtained for study data collection, where necessary, according to local regulations. exclusion criteria: 1. participants for whom the minimum study dataset is not available from their hospital medical records. 2. participants who have participated in an interventional clinical trial at any stage of their chl (group 1) or rrhl (group 2) management.

Keywords: drug therapy
endothelial function in prehypertension

Conditions: Hypertension,Essential

Summary: in the frame of this proposal investigators will test the hypothesis that high normal blood pressure (prehypertension; preht) induces systemic endothelial dysfunction and endothelial activation in both micro- and macrocirculation, reduces re-endothelialization potential of human endothelial progenitor cells (epcs) and increases the level of endothelial extracellular vesicles (evs), which are accompanied by increased oxidative stress level. furthermore, initial vascular and left ventricle (lv) remodeling contributes to changes in systemic hemodynamics and may be influenced by altered regulatory role of renin-angiotensin system (ras) and autonomic nervous system (ans) in preht but otherwise healthy individuals. to distinguish high normal blood pressure effect from those considered normal or high, study will be performed in three groups of individuals: prehypertensive (bp 130-139/85-89 mmhg), hypertensive (stage i, bp 140-150/90-100 mmhg), and controls (bp less than or equal to 129/85 mmhg). altogether, the impairment of normal vascular relaxation mechanisms, endothelial activation as well as vascular and lv remodeling could play crucial role in increased cardiovascular risk and cvds incidence in preht individuals. moreover, the prognostic significance of assessing endotehlial dysfunction in hypertension (as well as in preht) is yet to be established.


Eligibility criteria:
inclusion criteria: * adults of both sexes with normotensive, prehypertensive and grade i hypertension blood pressure values exclusion criteria: * cardiovascular diseases, but grade i hypertension (bp 140-150/90-100 mmhg) * diabetes * kidney disease * cerebrovascular diseases * peripheral artery disease * taking oral contraceptives or any drugs that could affect the endothelium

Keywords: hypertension prehypertension endothelium left ventricle hemodynamics
a cryotherapy with tranexamic acid versus normal saline in the treatment of melasma

Conditions: Cryotherapy Effect

Summary: this study aimed to evaluate the effectiveness of a precision cryotherapy via boosting mode combined with tranexamic acid versus normal saline in the treatment of melasma. eighteen patients aged 25 to 60 years diagnosed with epidermal-typed melasma sized equal to or more than 2 cm on both cheeks were included. the patients were treated with a precision cryotherapy via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week. then, they were follow up at 1 and 3 months after the last treatment. subjective assessment of physician and patient improvement were evaluated. moreover, melasma area and severity index (masi), melanin and erythema index using mexameter were also recorded.

targetcool via boosting mode combined with tranexamic acid versus normal saline were studied in patients diagnosed with epidermal-typed melasma.

Eligibility criteria:
inclusion criteria: * the patients diagnosed with epidermal-type melasma sized equal to or more than 2 cm on both sides of cheeks * fitzpatrick skin type ii-iv exclusion criteria: * pregnant or lactation * subjects who have been treated with any kind of energy-based device 6 months prior to the inclusion * subjects who have been treated with topical or oral treatment for melasma 6 months prior to the inclusion * subjects who allergy to cryotherapy such as cryoglobulinemia, cold urticaria, and abnormal cold tolerance * subjects with abnormal sensation such as diabetes mellitus * active skin infections * history of hypertrophic scars or keloids history of hypertrophic scars or keloids
the effect of complementary medicine (cam) treatments on common symptoms in hospitalized patients

Conditions: Pain; Nausea; Anxiety

Summary: this is a randomized, single blinded, interventional trial conducted in patients undergoing elective laparoscopic cholecystectomy, comparing the following three groups: controls receiving standard-of-care (soc) only (group 1); intervention group receiving reflexology and soc (group 2); and a group receiving sham reflexology and soc (group 3). in all groups, level of preoperative anxiety was evaluated at entry and exit from the holding room area (hra). the evaluation was carried out using the visual analogue scale for anxiety (vas-a) questionnaire.


Eligibility criteria:
inclusion criteria: 1. patients aged 18 years 2. undergoing laparoscopic cholecysyectomy (lc) exclusion criteria: 1. patients with a history of obstructive sleep apnea 2. contraindication for benzodiazepines 3. hemodynamic instability 4. leg ulcers 5. patients undergoing a lc together with another surgical procedure.

Keywords: complementary medicine hospitalized
single ascending dose study of prx002 in healthy subjects

Conditions: Parkinson's Disease

Summary: this single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of prx002 in approximately 40 healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy subjects * body mass index (bmi) between 18-32 kg/m2 with a minimum weight of 46 kg * female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception * male subjects and their partners of childbearing potential must use contraception exclusion criteria: * positive test for drug of abuse * past or current history of alcohol abuse * positive for hepatitis b, hepatitis c or hiv infection
transfoveal micropulse laser for center involving diabetic macular edema

Conditions: Diabetic Retinopathy; Macula Edema

Summary: anti-vascular endothelial growth factor (vegf) therapy is currently the mainstay of treatment for diabetic macular edema (dme). one of the main obstacles of anti-vegf therapy is the need of repeated injections, which carries both economic and compliance problems to the patients.there is a growing evidence that recognises the effectiveness of the use of micropulse laser (mpl) in treatment of dme. with mpl, it is possible to deliver a subthreshold laser that is above the threshold of biochemical effect but below the threshold of a visible, destructive lesion thereby preventing collateral damage.the mpl technique is available at near - infrared 810 nm diode laser (diode mpl) and at 577 nm (yellow mpl). the current study was conducted in order to compare the efficacy of both mpl techniques in the treatment of center involving dme.

this was a prospective randomized comparative study that included 30 eyes of 15 patients with bilateral dme. the patients were recruited from the retina clinic at kasr al ainy hospital, cairo university. the study's protocol was reviewed and approved by board of the ophthalmology department, cairo university, and was in concordance with the tents of declaration of helsinki. eligible patients were informed about the study's objectives, methodology, risks and benefits. a written informed consent was obtained from every patient included in this study.preliminary examination was in the form of slit-lamp examination, fundus examination, intra ocular pressure measurement, and best corrected visual acuity (bcva) measurement. a spectral domain optical coherence tomogram (oct) scan was performed to all patients before treatment to measure the central retinal thickness (crt). the eyes were randomized into two groups; one eye (right eye) of each patient was treated with 577-nm yellow mpl and the other eye (left eye) of the same patient with infrared 810-nm diode mpl. changes in the bcva and crt were measured after treatment at 1 and 3 months of follow up.

Eligibility criteria:
inclusion criteria: * bilateral diabetic macular edema * center involving confirmed by optical coherence tomogram (oct) exclusion criteria: * any non-diabetic macular edema * significant media opacities * previous laser treatment, any intraocular surgery within the past 6 months * previous intravitreal injections of any drug within the past 6 months

Keywords: micro-pulse laser trans-foveal
a genetic analysis of usher syndrome in ashkenazi jews

Conditions: Usher Syndrome; Retinitis Pigmentosa; Congenital Hearing Impairment

Summary: hearing loss and loss of vision can be very harmful to the well-being and life of people who suffer from them. usher syndrome is the name of a disease where people have both hearing loss and visual loss. in fact more than half of people who are deaf and blind have usher syndrome. in this study we are trying to find the causes of all types of usher syndrome and to learn more about how the eyes and ears work. usher syndrome is caused by changes in our genes that lead to mistakes in the functioning of our eyes and ears. we may conduct hearing tests called audiograms to test hearing and a vision test called an electroretinogram (erg) to test how well the retina (the part of your eye that senses light) is working on participants in the study. from these tests we can tell what kind of usher syndrome a participant may have. we will then get dna from participants by drawing blood. the dna will be studied, along with dna from members of the participant's family and other families, to try to find the gene that is causing usher syndrome in the participant. once the gene is found we will be able to study it to learn more about how the eyes and ears work. if a subject has already been diagnosed we may just need copies of their medical records and blood can be drawn locally. in order to increase the power of the study and the likelihood of detecting relevant genes participants will be taken from the ashkenazi jewish population group only. this will make it much easier to find the genes.


Eligibility criteria:
inclusion criteria: any ashkenazi jewish individual with combined hearing and visual loss that is or may be any type of usher syndrome, or a family member of said individual. exclusion criteria: any individual who is not an ashkenazi jew or does not have combined hearing and visual loss or whose disease has been previously determined not to be usher syndrome.
voice analysis in asthmatic patients with machine learning models

Conditions: Asthma

Summary: asthma can lead to various factors that impair voice production, including airway restriction, inflammation, and mucus production, resulting in changes in voice frequency and amplitude. therefore, voice analysis may serve as an indicator of respiratory diseases. a national, observational, case-control study is planned in türkiye to analyze differences in voice between healthy subjects and asthmatic patients and to assess voice analysis techniques for determining an effective biomarker for asthma control using a machine learning model.

asthma is a disease characterized by chronic inflammation. based on the frequency of symptoms and the use of reliever medications, the disease can be classified as either 'controlled' or 'uncontrolled'. currently, gina criteria and asthma control test can be used to evaluate asthma control. the relationship between respiratory functions and speech has been previously studied, revealing that voice changes can occur in asthmatic patients due to symptom presence. asthma can lead to various factors that impair voice production, including airway restriction, inflammation, and mucus production, resulting in changes in voice frequency and amplitude. therefore, voice analysis may serve as an indicator of respiratory diseases. understanding the alterations in phonation/voice due to the underlying disease is crucial. this study seeks to analyze differences in voice between healthy subjects and asthmatic patients and to assess voice analysis techniques for determining an effective biomarker for asthma control using a machine learning model. this is a national, observational, cross-sectional study that will be conducted in türkiye. the study consists of two stages: in the first stage, a machine learning (ml) model will be developed using voice data collected from both healthy individuals and patients diagnosed with asthma. in the second stage, this ml model will be tested to detect voice differences among patients at different levels of asthma control.

Eligibility criteria:
asthmatic group inclusion criteria: * patients diagnosed with asthma according to gina criteria and pulmonary function test, and followed for at least three months * 18-65 years of age. * sign an informed consent document * able to comply with the study protocol during the study period. exclusion criteria: * none healthy group inclusion criteria: * healthy participants between 18-65 years of age * good general health * no history of chronic respiratory disorders * no history of chronic systemic disorders * no history of upper respiratory tract infections within five days prior voice recording. exclusion criteria: * none

Keywords: voice biomarker machine learning
progressive muscle relaxation exercise on intensive care nurses

Conditions: Occupational Stress

Summary: nurses who intensive care unit will be entered. participants will be randomized to one of two study arms: arm 1: progressive muscle relaxation; arm 2: control. hypothesis: progressive muscle relaxation will decrease occupational stress, headache and improve well-being.

previous reports have revealed that non-pharmacological approaches such as aromatherapy, massage, meditation, music therapy, breathing exercises, yoga and progressive muscle relaxation exercises (pge) have been used to reduce stress and fatigue of individuals and improve their well-being. however, there have been limited studies that directly focus on supporting intensive care nurses who face serious problems with intense work tempo, experience excessive stress, headache, tension, fatigue, are open to psychosocial problems such as anxiety, depression and burnout. besides, till date, no study has been conducted to determine the effects of progressive relaxation exercise on occupational stress, headache and well-being for intensive care nurses. the present study investigates the effects of progressive muscle relaxation in a single-site, 2-arm, assessor-blinded randomized, controlled study of 100 intensive care nurses. arm 1: relaxation; arm 2: attention matched control. the investigators hypothesize that progressive muscle relaxation will decrease the severity of occupational stress and headache and improve well-being.

Eligibility criteria:
inclusion criteria: * working in cardiovascular intensive care for at least 6 months * having a headache at least once a week * no physical disability * those who do not have a neurological diagnosis (having cerebrovascular disease, multiple sclerosis, etc.) * no psychiatric diagnosis * not applying any complementary methods at the time the research was conducted. * nurses who volunteered to participate in the study exclusion criteria: * nurses followed up with the diagnosis of end-stage renal disease, chronic obstructive pulmonary disease, advanced heart failure, chronic liver disease, musculoskeletal problem, hypothyroidism and depression * having physical and mental health problems that prevent communication * nurses who practiced any complementary method (relaxation exercise, yoga, etc.) during the study.

Keywords: headache intensive care units occupational stress relaxation well-being
gabapentin for perioperative pain relief in surgical abortion

Conditions: Pain Control

Summary: gabapentin preoperative use for evaluation of benefit to reduce pain during and after surgical office-based abortion.

a double-blind placebo controlled trial of gabapentin in the setting of an ambulatory surgical abortion center where patients receive either the routine intravenous sedation, local cervical anesthesia plus 600mg of gabapentin one hour prior to surgery vs. the same regimen plus placebo one hour prior to surgery. our primary outcome measure will be post-operative validated pain scores using a 11-point visual analog scale (vas). secondary measures will include nausea and vomiting during, after and 24 hours after the procedure. a second and third pain assessment using vas will be made at 30 minutes and at 24 hours postoperatively.

Eligibility criteria:
inclusion criteria: * women seeking surgical abortion between 5 and 23 6/7 weeks of ultrasound age. * english or spanish speaking * eligible for office-based surgical pregnancy termination exclusion criteria: * present use of gabapentin or pregabalin, * renal disease * sensitivity or allergy to gabapentin * missed abortion

Keywords: gabapentin abortion